Infinity Announces Closing of Public Offering and Exercise of Over-Allotment Option
Infinity Pharmaceuticals (NASDAQ: INFI) today announced the closing of its previously announced underwritten registered public offering of common stock. The total number of shares of common stock sold was 6,551,461, composed of 5,696,923 shares of common stock initially offered and an additional 854,538 shares of common stock sold pursuant to the exercise of the underwriters' over-allotment option, in each case at a public offering price of $26.33 per share. All of the shares in the offering were sold by Infinity. The gross proceeds to Infinity from the offering, before deducting underwriting discounts and commissions and offering expenses, are approximately $172.5 million.
The joint book-running managers for the offering were Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC. BofA Merrill Lynch and Deutsche Bank Securities Inc. acted as co-lead managers. Additionally, Stifel Nicolaus Weisel acted as co-manager.
The securities described above were offered by Infinity pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission (SEC). The final prospectus supplement and accompanying prospectus related to this offering are located on the SEC's website, www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus may also be obtained from:
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.